Overall, this research demonstrates the potential of the AdenoSig signature to predict responses to the A2AR antagonist ciforadenant in RCC, positioning it as a valuable tool for selecting patients likely to benefit from adenosine-targeting therapies. Here, ADORA2A is linked to renal cell carcinoma.